LIF and breast carcinoma: While ER+ breast cancer cell lines were used in the initial screens for LIF and LIFR in these studies, functional studies were all carried out in TNBC cell lines, so it is unclear whether EC359 would have had similar effects on ER+ tumor progression in vivo.